Our results showed that down‐regulation of H19 combined with Gefitinib administration significantly improved the effect of shH19 treatment alone on the progression of NSCLC, which was involved in the activation of PTEN signalling pathway in NSCLC in vivo. The gene discussed is H19; the disease is non-small cell lung carcinoma.